IL-2 Activator

IL-2 Activators (24):

Cat. No.	Product Name	Effect	Purity

HY-Y0344D

Sodium chloride, for cell culture	Activator	99.9%
Sodium chloride, for cell culture is an orally active salt. Sodium chloride, for cell culture induces the expression of ATP1A1. Sodium chloride, for cell culture induces the pro-inflammatory cytokines IL-2, TNFα, IL-9 and several chemokines. Sodium chloride, for cell culture enhances the anti-tumor activities of Digoxin (HY-B1049) against small cell lung cancer. Sodium chloride, for cell culture drives autoimmune disease by the induction of pathogenic Th17 cells.

HY-P99152

Muromonab	Activator	98.74%
Muromonab (Muromonab-CD3; OKT3) is a mouse monoclonal antibody targeting the CD3 antigen. Muromonab specifically binds to the CD3 antigen on the surface of human and higher primate T cells. Muromonab blocks the function of T cell receptors to recognize foreign antigens and inhibits T cell-mediated immune responses, including cell-mediated lymphocyte lysis and T cell proliferation responses. Muromonab can be used to study acute kidney, liver, heart and combined kidney-pancreas transplant rejection, and can also be used to study graft-versus-host disease in bone marrow transplant patients.

HY-P99159

Ivuxolimab	Activator	≥99.0%
Ivuxolimab is a fully human IgG2 agonist targeting OX40 (CD134), which selectively binds to the OX40 receptor on the surface of activated CD4⁺ and CD8⁺ T cells without inducing antibody-dependent cytotoxicity. Ivuxolimab can promote T cell proliferation, survival and cytokine (such as IFN-γ, IL-2) secretion, inhibit regulatory T cell function, and enhance anti-tumor immune response. Ivuxolimab can be used in the study of melanoma, hepatocellular carcinoma, head and neck squamous cell carcinoma, etc.

HY-181924

HPK1-IN-68	Activator
HPK1-IN-68 (Compound 39) is a HPK1 inhibitor with an IC₅₀ of 2.8 nM. HPK1-IN-68 blocks HPK1 signaling, inhibits HPK1-mediated phosphorylation of SLP76, and promotes the production of the IL-2 cytokine. HPK1-IN-68 antagonizes the immunosuppressive effect mediated by PGE2. HPK1-IN-68 enhances the infiltration of CD3⁺/CD8⁺ T cells into tumor tissues. HPK1-IN-68 exerts T cell-dependent antitumor efficacy in a mouse colon cancer model. HPK1-IN-68 exhibits significant synergistic antitumor effects when used in combination with anti-PD-1. HPK1-IN-68 is applicable to research related to colon cancer.

HY-P991960

JS007	Activator
JS007 is a humanized IgG1 monoclonal antibody and also a CTLA-4 binder, with a K_d of 0.21 nM for CTLA-4. JS007 blocks the interaction between CTLA-4 and B7-1. JS007 activates T cells, promotes increased IL-2 secretion, and inhibits tumor growth in CTLA-4 knock-in mouse syngeneic tumor models. JS007 is applicable to research related to cancer and advanced solid tumors.

HY-N0534

Vitexin-2"-O-rhamnoside	Activator	99.78%
Vitexin-2"-O-rhamnoside is an orally active flavonoid glycoside. Vitexin-2"-O-rhamnoside inhibits Apoptosis, increases the phosphorylation levels of PI3K/Akt, inhibits caspase-3, SOD activity, and promotes cytokine (IL-2, IL-6, and IL-12) secretion. Vitexin-2"-O-rhamnoside strongly inhibits DNA synthesis in MCF-7 cells with an IC₅₀ of 17.5 μM. Vitexin-2"-O-rhamnoside enhances immune function and improves the absorption of active compounds. Vitexin-2"-O-rhamnoside has antioxidant activity. Vitexin-2"-O-rhamnoside is used in the study of cardiovascular disease and immune-related diseases.

HY-Y0344J

Sodium chloride, for molecular biology	Activator	99.97%
Sodium chloride is an orally active salt. Sodium chloride induces the expression of ATP1A1. Sodium chloride induces the pro-inflammatory cytokines IL-2, TNFα, IL-9 and several chemokines. Sodium chloride enhances the anti-tumor activities of Digoxin (HY-B1049) against small cell lung cancer. Sodium chloride drives autoimmune disease by the induction of pathogenic Th17 cells.

HY-Y0344I

Sodium chloride, meets analytical specification of Ph. Eur. BP USP, ≤0.00002% Al	Activator	99.99%
Sodium chloride, meets analytical specification of Ph. Eur. BP USP, ≤0.00002% Al, an inorganic salt is an orally active salt. Sodium chloride, meets analytical specification of Ph. Eur. BP USP, ≤0.00002% Al, an inorganic salt induces the expression of ATP1A1. Sodium chloride, meets analytical specification of Ph. Eur. BP USP, ≤0.00002% Al, an inorganic salt induces the pro-inflammatory cytokines IL-2, TNFα, IL-9 and several chemokines. Sodium chloride, meets analytical specification of Ph. Eur. BP USP, ≤0.00002% Al, an inorganic salt enhances the anti-tumor activities of Digoxin (HY-B1049) against small cell lung cancer. Sodium chloride, meets analytical specification of Ph. Eur. BP USP, ≤0.00002% Al, an inorganic salt drives autoimmune disease by the induction of pathogenic Th17 cells.

HY-P991208

Flt-3L-Ig (hum/hum)	Activator	98%
Flt-3L-Ig (hum/hum) (hFlt3L) is a Flt3 ligand. Flt-3L-Ig (hum/hum) enhances the release of inflammatory cytokines from myeloid cells and dendritic cells in BRGSF-CBC mice induced by OKT3. Flt-3L-Ig (hum/hum) increases the release of IL-2, CCL2 and CXCL10 in an OKT3-dependent manner. Flt-3L-Ig (hum/hum) can be used in studies related to cytokine release syndrome. Flt-3L-Ig (hum/hum) can be used in studies related to psoriasis-like skin inflammation.

HY-159892

PD-1/PD-L1-IN-54	Activator
PD-1/PD-L1-IN-54 (Compound 6) is a moderately affinic PD-1/PD-L1 inhibitor (K_D: PD-1, 55.8 μM; PD-L1, 46.4 μM; IC₅₀: 88.6 μM). PD-1/PD-L1-IN-54 inhibits PD-1/PD-L1 interactions and shows anticancer activity by activating CD8⁺ T cells, upregulating PD-1 expression, and increasing secretion of IFN-γ and IL-2. PD-1/PD-L1-IN-54 inhibits cancer cell proliferation and promotes apoptosis. PD-1/PD-L1-IN-54 also regulates T cell immunity through the PI3K/Akt pathway correlated with PD-1/PD-L1.

HY-183317

IDO1-IN-34	Activator
IDO1-IN-34 is a selective IDO1 inhibitor with an IC₅₀ of 0.093 μM. IDO1-IN-34 exhibits cytotoxicity against various cancer cell lines. IDO1-IN-34 inhibits the kynurenine (kynurenine) pathway and activates IL-2. IDO1-IN-34 induces cell apoptosis via the endogenous mitochondrial pathway, while increasing the levels of cytochrome c, caspase-3, caspase-9 and PARP-1. IDO1-IN-34 can be used for research on liver cancer, lung cancer, breast cancer, prostate cancer, colon cancer and leukemia.

HY-P992457

SAR444200	Activator
SAR444200 is a nanobody T-cell engager targeting GPC3 (glypican-3) and TCRαβ (T-cell receptor αβ). SAR444200 has a K_D of 0.023 nM for human GPC3 and a K_D of 5.2 nM for human TCRαβ. SAR444200 mediates T-cell-dependent cytotoxicity, with high selectivity and killing activity against GPC3-positive tumor cells. SAR444200 binds to GPC3 in a dual-epitope manner, and binds to TCRαβ via its N-terminal nanobody, forming an artificial immunological synapse between T cells and tumor cells. SAR444200 can be used for the research of GPC3⁺ solid tumors, including liver cancer, lung squamous cell carcinoma and melanoma.

HY-Y0344H

Sodium chloride, United States Pharmacopeia (USP) Reference Standard	Activator
Sodium chloride, United States Pharmacopeia (USP) Reference Standard is an orally active salt. Sodium chloride, United States Pharmacopeia (USP) Reference Standard induces the expression of ATP1A1. Sodium chloride, for cell culture induces the pro-inflammatory cytokines IL-2, TNFα, IL-9 and several chemokines. Sodium chloride, United States Pharmacopeia (USP) Reference Standard enhances the anti-tumor activities of Digoxin (HY-B1049) against small cell lung cancer. Sodium chloride, United States Pharmacopeia (USP) Reference Standard drives autoimmune disease by the induction of pathogenic Th17 cells.

HY-180898

AHL-7160	Activator
AHL-7160 is a covalent DGKα inhibitor that possesses dual functions of enzyme activity inhibition (IC₅₀ ≈ 12 nM) and molecular gel-mediated degradation. AHL-7160 can rapidly recruit endogenous DGKα to the cell membrane (EC₅₀ = 39 nM), and this effect has isozyme selectivity. AHL-7160 can stereospecifically block phosphatidylcholine acid (PA) production mediated by DGKα (IC₅₀ = 340 nM). AHL-7160 enhances T cell activation and promotes anti-tumor immune responses. AHL-7160 can be used for research on immunotherapy.

HY-123221

RS-0481	Activator
RS-0481 is an orally active lymphocyte population function restorer. RS-0481 enhances IL-2 production activity. RS-0481 can re-establish the function of certain lymphoid cell populations impaired by the presence of a growing tumor in an animal. RS-0481 markedly augments the tumor-specific cytotoxic T lymphocytes, T_DTH, and the nonspecific lymphokine-activated-killer-cell-like cell responses.

HY-113271

5-Androstenetriol	Activator
5-Androstenetriol is a systemic radiation protector that can boost the host's immunity, leading to increased resistance to infections. 5-Androstenetriol can raise levels of IL-2, IL-3, and IFN, while countering the immunosuppressive effects of Hydrocortisone (HY-N0583).

HY-P992401

M802	Activator
M802 is an anti-HER2/CD3 bispecific antibody, with a K_d of 0.578 nM for human HER2 and a K_d of 71.2 nM for human CD3. M802 inhibits the PI3K/AKT and MAPK signaling pathways, suppresses tumor cell proliferation, activates caspase-3, and promotes tumor cell apoptosis (apoptosis). M802 recruits and activates CD3-positive immune cells, mediates cytotoxicity against HER2-positive tumor cells, and induces immune cells to secrete IFN-γ, TNF-α, IL-2 and IL-6. M802 exhibits anti-tumor efficacy in mice with gastric cancer xenografts. M802 can be used in research related to HER2-positive breast cancer, HER2-positive gastric cancer and other cancers. The recommended isotype control is human IgG1 kappa (HY-P99001).

HY-179338

HPK1-IN-65	Activator
HPK1-IN-65 is a selective and orally active HPK1 inhibitor with an IC₅₀ value of < 5 nM. HPK1-IN-65 inhibits HPK1 kinase activity and displays 1257-fold selectivity over the MAP4K kinase family member GLK. HPK1-IN-65 exhibits an IC₅₀ of 92.3 nM for inhibiting pSLP76 phosphorylation. HPK1-IN-65 demonstrates an EC₅₀ of 398 nM for stimulating IL-2 production. HPK1-IN-65 inhibits TCR-induced phosphorylation of SLP76 at Ser376 in a dose-dependent manner. HPK1-IN-65 can be further utilized for colorectal cancer research.

HY-186140

SHP1-IN-2	Activator
SHP1‑IN‑2 is a selective and orally active SHP1 inhibitor. SHP1‑IN‑2 covalently binds to Cys480 of SHP1. SHP1‑IN‑2 elicits potent antitumor immunity and suppresses syngeneic tumor growth. SHP1‑IN‑2 blocks tumor progression in a svngeneic cancer model by activating natural killer cells and cytotoxic CD8^＋ T cells, along with reduced T cel l. SHP1‑IN‑2 can be used for cancer‑related research.

HY-P992434

OSE-279	Activator
OSE-279 is a high-affinity humanized monoclonal bivalent antibody targeting PD-1, the recommended isotype control is HY-P99003. OSE-279 blocks PD-1 ligand binding, inhibits PDL1-induced SHP1 phosphorylation, restores T cell activation, and promotes reactivation of primary T cell effector functions. OSE-279 binds hFcRn receptor, predicts long half-life, induces CD4 and CD8 T cell proliferation, and promotes interleukin 2 and interferon gamma secretion. OSE-279 can be used for the research of advanced malignancies, colon cancer, hepatocarcinoma, mesothelioma.

Name
Email *

	Sorry, but the email address you supplied was invalid.